Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2‐positive metastatic breast cancer: An Australian case series

Autor:	Saw Yee Yap, Vishal Boolell, Peter Savas, Robin Stuart-Harris, Alice R T Bergin, Stephen J Luen, Louise M. Nott, Lee Na Teo, Doah Cho, Jodi Lynch, Sherene Loi
Rok vydání:	2019
Předmět:	Adult Bridged-Ring Compounds Oncology medicine.medical_specialty Receptor ErbB-2 Breast Neoplasms Antibodies Monoclonal Humanized 03 medical and health sciences 0302 clinical medicine Breast cancer Median follow-up Trastuzumab Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Clinical endpoint Humans 030212 general & internal medicine neoplasms Retrospective Studies Taxane business.industry Australia General Medicine Middle Aged medicine.disease Metastatic breast cancer Docetaxel 030220 oncology & carcinogenesis Female Taxoids Pertuzumab business medicine.drug
Zdroj:	Asia-Pacific Journal of Clinical Oncology. 15:377-382
ISSN:	1743-7563 1743-7555
DOI:	10.1111/ajco.13195
Popis:	Background Pertuzumab, when combined with trastuzumab and chemotherapy, is a highly active human epidermal growth factor receptor 2 (HER2), targeting agent in the neoadjuvant, adjuvant and first-line metastatic HER2-positive breast cancer setting. The efficacy of late-line (after first/second-line) pertuzumab in combination with trastuzumab and chemotherapy is unknown. Aims To establish pertuzumab efficacy by performing an audit of patients who received pertuzumab after first-line HER2 directed therapy. We sought to establish whether efficacy differed by clinicopathological factors. Methods The primary endpoint was progression-free survival (PFS) and the secondary endpoint, overall survival (OS). Clinicopathological factors, PFS and OS data were collated and clinicopathological factors associated with PFS were evaluated using Cox regression models. Results Fourteen women were identified. Six (43%) had hormone receptor (HR) negative and eight (57%) had HR-positive, metastatic HER2-positive breast cancer. Median follow up was 22.8 months, median prior lines of therapy were 5 (range: 1-9). Median time from diagnosis of metastatic disease to receiving pertuzumab was 4.5 years (range: 4.2-5.8). All patients received initial chemotherapy with pertuzumab and trastuzumab (taxane-based 71%). Median PFS was 9 months (95% confidence interval [CI]: 7-not estimable [NE]) and median OS was not reached (95% CI, 16 months-NE). Univariable analysis demonstrated that HR-negative patients had a significantly longer PFS than HR-positive patients (hazard ratio = 0.11; 95% CI, 0.01-0.88; P = 0.04). Conclusion This small cases series reports a favorable PFS and OS for pertuzumab with trastuzumab and chemotherapy in the later line metastatic setting. This finding warrants further study.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8f8cd6ac537164489b9a1b13584edf6 https://doi.org/10.1111/ajco.13195 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.